Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
NeoplasmHepatocellular Carcinoma
Interventions
BIOLOGICAL

Pegylated Recombinant Human Arginase I

Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg

Trial Locations (1)

Unknown

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

collaborator

Chinese University of Hong Kong

OTHER

lead

Bio-Cancer Treatment International Limited

INDUSTRY

NCT01092091 - Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) | Biotech Hunter | Biotech Hunter